Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085774 | 1.00 | MAPT (0.43) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3087284 | 0.90 | MAPT (0.44) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3087288 | 0.90 | MAPT (0.44) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11349724 | 0.89 | MAPT (0.41) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11348613 | 0.89 | MAPT (0.41) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3079557 | 0.89 | MAPT (0.41) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3992059 | 0.89 | MAPT (0.41) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3079561 | 0.89 | MAPT (0.41) | MAPTCACNA1CALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3992061 | 0.84 | DRD2 (0.34) | MAPTCACNA1CALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4107171 | 0.82 | ALDH1A1 (0.39) | MAPTALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F8 | MAPT 1524/4885CACNA1C 3504/4885ALDH1A1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.